• Who we are

Leadership Team

Nicolas Fischer, CEO

nicolas fischer

After obtaining a PhD in molecular biology, Nicolas joined the group of Greg Winter (2018 Nobel prize for chemistry) at the Medical Research Council in Cambridge (UK) to work on in vitro evolution of proteins and antibody engineering.

At Novimmune since 2002, he led several therapeutic antibody programs. Then, as the Head of Research, he focused on the development of the κλ body bispecific antibody platform which is now the core technology of Light Chain Bioscience.

Back

New publication in Frontiers

Targeting CEACAM5-positive solid tumors using NILK-2401, a novel CEACAM5xCD47 κλ bispecific antibody


Read more

LinkedIn